Paper Details

  1. Home
  2. Paper Details

Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.

Author: AliAskal Ayalew, BabcockAram, BalkrishnanRajesh, DiabyVakaramoko, MonteroAlberto

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

CDK 4/6 inhibitors are a new class of oral anticancer medications that have shown promise in treating metastatic breast cancer. While these drugs have shown benefits, their effectiveness is influenced by factors like adherence, sociodemographic factors, and side effects. This commentary discusses the need for further research on the real-world effectiveness and cost-effectiveness of these medications, especially in underserved populations, to fully understand their value.
Paper Details　
Original Abstract of the Article :
Despite the achieved advancement in pharmacological cancer treatments, the majority of postmenopausal women with hormone receptor-positive metastatic breast cancer (mBC) will experience disease progression. Research into alternative therapies with improved efficacy and reduced side effects has led t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391228/

データ提供：米国国立医学図書館（NLM）

Palbociclib for Metastatic Breast Cancer: A Real-World Perspective

The world of breast cancer treatment is a vast and constantly evolving desert, where new therapies are constantly being developed to combat this challenging disease. This commentary delves into the real-world clinical and economic outcomes associated with palbociclib, a CDK 4/6 inhibitor, in treating HR-positive/HER2-negative metastatic breast cancer (mBC). It explores the challenges of ensuring optimal effectiveness and addressing the cost-effectiveness of this promising new therapy.

A New Oasis for Metastatic Breast Cancer?

The commentary discusses the potential benefits of palbociclib, a new class of oral anticancer medications that has shown promise in treating mBC. It's like discovering a new oasis in the desert, offering a source of hope and potential for better treatment outcomes. However, the commentary also highlights the challenges associated with palbociclib, including low adherence, sociodemographic factors, and adverse effect profiles.

Navigating the Desert of Cost-Effectiveness

The commentary emphasizes the disconnect between the high cost of CDK 4/6 inhibitors and their observed effectiveness, raising concerns about their value and affordability. It's like encountering a treacherous sandstorm in the desert, forcing us to consider the risks and rewards of venturing forward. The commentary calls for further research to explore the real-world effectiveness and cost-effectiveness of these new therapies, ensuring that they provide a true benefit to patients.

Dr.Camel's Conclusion

This commentary provides a valuable real-world perspective on palbociclib, a promising new therapy for mBC. While palbociclib offers potential benefits, the commentary highlights the need for further research to address challenges related to adherence, side effects, and cost-effectiveness. It's a reminder that the desert of breast cancer treatment is vast and complex, requiring a careful balance between innovation and practicality.

Date :
  1. Date Completed 2021-04-01
  2. Date Revised 2023-08-03
Further Info :

Pubmed ID

32584682

DOI: Digital Object Identifier

PMC10391228

Related Literature

Article Analysis
・Side Effects of ribociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.